Equitable Access to High-Cost Pharmaceuticals
Cover -- Title Page -- Copyright Page -- Dedication -- Contents -- Contributors -- Foreword -- Chapter 1 - Access to High Cost Medicines: An Overview -- Abbreviations -- 1.1 - Defining HCMs -- 1.2 - Value of HCMs -- 1.3 - Accessibility of HCMs -- 1.4 - Approaches for promoting access to HCMs -- 1.5 - Conclusion -- Note -- References -- Chapter 2 - Health Technology Assessment -- 2.1 - Introduction -- 2.2 - What is health technology assessment (hta)? -- 2.3 - Technologies -- 2.4 - Principles underpinning HTA processes -- 2.5 - Evidence-based decision-making for the subsidy of health technologies -- 2.5.1 - Criteria Used to Inform Subsidy Decisions -- 2.5.2 - Threshold for Value for Money -- 2.5.3 - Considering Multiple Criteria in Decision-making -- 2.6 - Who's involved? Stakeholders at the table -- 2.7 - Future directions in health technology assessment for high cost medicines -- 2.8 - Summary -- References -- Chapter 3 - High-Cost Medicines in England -- 3.1 - Introduction -- 3.2 - Background -- 3.2.1 - Policy in History -- 3.2.2 - National Arrangements -- 3.2.3 - NICE Guidance -- 3.2.4 - The Carter Review -- 3.3 - High-cost drugs -- 3.3.1 - Specialised Services -- 3.3.2 - Cancer Drugs Fund -- 3.3.3 - Hospital Medicines Optimisation -- 3.4 - The way ahead -- 3.5 - Conclusions -- References -- Further Reading -- Chapter 4 - Managed Entry Agreements and High Cost Medicines (European Perspective) -- 4.1 - Rationale for mea -- 4.2 - Definition and taxonomy of mea -- 4.3 - Diffusion of mea in europe -- 4.4 - Impact evaluation and future perspectives -- References -- Chapter 5 - Setting a Public Health Agenda to Support Access to High-Cost Medicines -- 5.1 - Introduction -- 5.2 - The emerging significance of the impact of high-cost medicines -- 5.3 - European cooperation -- 5.4 - G7 and G20 -- 5.5 - The un high-level panel on access to medicines